Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as $57.23 and last traded at $57.23, with a volume of 859 shares traded. The stock had previously closed at $63.79.
Wall Street Analysts Forecast Growth
Separately, William Blair upgraded Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.
Read Our Latest Report on Zealand Pharma A/S
Zealand Pharma A/S Stock Down 10.3%
The company's fifty day simple moving average is $66.61 and its 200 day simple moving average is $84.98. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $4.06 billion, a PE ratio of -24.25 and a beta of 0.74.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.10. The company had revenue of $1.14 million for the quarter, compared to analyst estimates of $248.61 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. Analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.
About Zealand Pharma A/S
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
